Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Stopped Investigational Drug removed from the market

Conditions

• Recurrent B-Cell Non-Hodgkin Lymphoma
• Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
• Recurrent Follicular Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Grade 3a Follicular Lymphoma
• Recurrent Lymphoplasmacytic Lymphoma
• Recurrent Mantle Cell Lymphoma
• Recurrent Marginal Zone Lymphoma
• Recurrent Nodal Marginal Zone Lymphoma
• Recurrent Splenic Marginal Zone Lymphoma
• Recurrent Waldenstrom Macroglobulinemia
• Refractory B-Cell Non-Hodgkin Lymphoma
• Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
• Refractory Follicular Lymphoma
• Refractory Grade 1 Follicular Lymphoma
• Refractory Grade 2 Follicular Lymphoma
• Refractory Grade 3a Follicular Lymphoma
• Refractory Lymphoplasmacytic Lymphoma
• Refractory Mantle Cell Lymphoma
• Refractory Marginal Zone Lymphoma
• Refractory Nodal Marginal Zone Lymphoma
• Refractory Splenic Marginal Zone Lymphoma
• Refractory Waldenstrom Macroglobulinemia

Interventions

• DRUG: Lenalidomide
• BIOLOGICAL: Ublituximab
• DRUG: Umbralisib

Sponsor

Yazeed Sawalha